NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
17.16
-0.83 (-4.61%)
At close: Jun 5, 2026, 4:00 PM EDT
17.11
-0.05 (-0.29%)
After-hours: Jun 5, 2026, 5:55 PM EDT
NovoCure Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 87.53 | 93.55 | 163.77 | 240.82 | 115.33 | 208.8 |
Short-Term Investments | 344.48 | 354.13 | 796.11 | 669.8 | 854.1 | 728.9 |
Cash & Short-Term Investments | 432 | 447.67 | 959.87 | 910.62 | 969.43 | 937.7 |
Cash Growth | -53.51% | -53.36% | 5.41% | -6.07% | 3.38% | 11.29% |
Accounts Receivable | 93.27 | 89.44 | 74.23 | 61.22 | 86.26 | 93.57 |
Other Receivables | 53.13 | 58.67 | 35.06 | 22.68 | 25.96 | 17.03 |
Total Trade Receivables | 146.4 | 148.1 | 109.29 | 83.9 | 112.22 | 110.59 |
Inventory | 43.46 | 41.11 | 35.09 | 38.15 | 29.38 | 24.43 |
Other Current Assets | 9.8 | 9.84 | 2.33 | 1.74 | 0.51 | 0.81 |
Total Current Assets | 631.66 | 646.73 | 1,107 | 1,034 | 1,112 | 1,074 |
Net Property, Plant & Equipment | 145.06 | 147 | 119.59 | 97.7 | 68.96 | 53.88 |
Other Long-Term Assets | 11.2 | 10.6 | 14.62 | 14.02 | 11.16 | 12.09 |
Total Assets | 787.93 | 804.33 | 1,241 | 1,146 | 1,192 | 1,140 |
Accounts Payable | 127.24 | 122.23 | 105.09 | 94.39 | 85.2 | 72.6 |
Accrued Expenses | 90.34 | 101 | 93.15 | 84.72 | 73.58 | 70 |
Current Portion of Long-Term Debt | - | - | 558.16 | - | - | - |
Total Current Liabilities | 217.58 | 223.23 | 756.39 | 179.12 | 158.78 | 142.6 |
Long-Term Debt | 195.46 | 195.05 | 97.3 | 568.82 | 565.51 | 562.22 |
Long-Term Leases | 39.48 | 41.65 | 19.97 | 27.42 | 18.76 | 13 |
Other Long-Term Liabilities | 4.69 | 3.94 | 6.94 | 8.28 | 7.43 | 11.19 |
Total Long-Term Liabilities | 239.63 | 240.63 | 124.21 | 604.52 | 591.7 | 586.4 |
Total Liabilities | 457.21 | 463.86 | 880.61 | 783.63 | 750.48 | 729 |
Additional Paid-in Capital | 1,697 | 1,634 | 1,520 | 1,353 | 1,222 | 1,100 |
Accumulated Other Comprehensive Income | -4.9 | -3.44 | -5.5 | -5.47 | -2.43 | -3.17 |
Retained Earnings | -1,362 | -1,290 | -1,154 | -985.5 | -778.46 | -685.93 |
Shareholders' Equity | 330.72 | 340.47 | 360.18 | 362.5 | 441.17 | 410.49 |
Total Liabilities & Equity | 787.93 | 804.33 | 1,241 | 1,146 | 1,192 | 1,140 |
Total Debt | 234.94 | 236.69 | 675.43 | 596.24 | 584.27 | 575.21 |
Net Cash (Debt) | 197.06 | 210.98 | 284.44 | 314.37 | 385.15 | 362.49 |
Net Cash Growth | -6.60% | -25.83% | -9.52% | -18.38% | 6.25% | -9.01% |
Net Cash Per Share | 1.75 | 1.89 | 2.64 | 2.96 | 3.68 | 3.47 |
Book Value | 330.72 | 340.47 | 360.18 | 362.5 | 441.17 | 410.49 |
Book Value Per Share | 2.94 | 3.05 | 3.34 | 3.41 | 4.22 | 3.93 |
Tangible Book Value | 330.72 | 340.47 | 360.18 | 362.5 | 441.17 | 410.49 |
Tangible Book Value Per Share | 2.94 | 3.05 | 3.34 | 3.41 | 4.22 | 3.93 |